This article is more than 5 years old. Information may no longer be current.
Top stories in endocrinology: Medication costs lower after bariatric surgery, FDA rejects dapagliflozin for type 1 diabetes
Among the top stories in endocrinology last week were findings that suggested spending on diabetes and hypertension medications may be substantially lowered after bariatric surgery and the FDA rejecting dapagliflozin to be used in conjunction with insulin for the treatment of type 1 diabetes.
Other highlights were from the Heart in Diabetes conference and included a study that found ethnicity, age and sex influence CV risk in people with type 2 diabetes, research that indicated severe hypoglycemic events can present cardiovascular and cognitive risks and a study that suggested insulin resistance is a more important cardiometabolic risk factor than glucose tolerance.
Medication costs lower after bariatric surgery
Spending on diabetes and hypertension medications may be substantially lowered after bariatric surgery, according to findings presented at the American Society for Metabolic and Bariatric Surgery national clinical symposium. Read more.
FDA rejects dapagliflozin indication as adjunctive therapy for type 1 diabetes
AstraZeneca today announced that the FDA has issued a complete response letter denying the attempt to expand the indications for dapagliflozin to be used in conjunction with insulin for treatment of type 1 diabetes. Read more.
Ethnicity, age, sex influence CV risk in type 2 diabetes
PHILADELPHIA — The growing global burden of type 2 diabetes and cardiovascular disease disproportionately affects people living in countries experiencing large social transitions, with women and those diagnosed before age 40 years more likely to experience worse disease outcomes, according to a speaker at the Heart in Diabetes conference. Read more.
Severe hypoglycemia indicates cardiovascular, cognitive danger
PHILADELPHIA — Severe hypoglycemic events can present cardiovascular and cognitive risks, and hypoglycemia should signal a call to action for physicians treating the patients with diabetes, a speaker said. Read more.
Influence of insulin resistance illustrates heightened CVD risk in ‘pre-prediabetes’
PHILADELPHIA — Insulin resistance is a more important cardiometabolic risk factor than glucose tolerance, increasing cardiovascular risk even before hyperglycemia increases the risk for diabetes. Read more.